Search Results

Group Of Employees Being Fired By Their Company.

Layoffs

Allakos Will Axe 75% of Workforce, Drop Hives Candidate

Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it explores strategic alternatives.

January 27, 2025

·

1 min read

·

Angela Gabriel

Press Releases

Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share

April 3, 2025

·

4 min read

Press Releases

Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results

March 13, 2025

·

6 min read

Press Releases

Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

January 27, 2025

·

5 min read

Business

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

Allakos Inc., a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, provided a business update and reported financial results for the first quarter ended March 31, 2024.

May 9, 2024

·

8 min read

Press Releases

Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results

November 7, 2024

·

8 min read

Drug Development

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

Allakos Inc. announced that the first patient with chronic spontaneous urticaria has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006.

May 28, 2024

·

5 min read

Drug Development

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

October 10, 2024

·

6 min read

Biotech Bay

Allakos Announces a Restructuring to Focus on Development of AK006

Allakos Inc. today announced a restructuring to reduce costs and to focus on AK006 clinical development and additional preclinical programs. As a result, the Company’s cash runway is expected to extend into mid-2026.

January 16, 2024

·

8 min read

Biotech Bay

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the publication of new scientific results in Allergy.

February 12, 2024

·

6 min read